How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017
Authors:
- 1 June 2019
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (6) , 2199-2205
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 31 references indexed in Scilit:
- Estimating the budget impact of orphan medicines in Europe: 2010 - 2020Orphanet Journal of Rare Diseases, 2011
- Moving towards universal health insurance in China: Performance, issues and lessons from ThailandSocial Science & Medicine, 2011
- Accelerating access to treatments for rare diseasesNature Reviews Drug Discovery, 2011
- Availability of and Access to Orphan DrugsPharmacoEconomics, 2011
- A comparative study of European rare disease and orphan drug marketsHealth Policy, 2010
- The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?Health Policy, 2010
- Orphan drug development is not taking offBritish Journal of Clinical Pharmacology, 2009
- Clinical research for rare disease: Opportunities, challenges, and solutionsMolecular Genetics and Metabolism, 2009
- Why rare diseases are an important medical and social issueThe Lancet, 2008
- Rare diseases and orphan drugsBritish Journal of Clinical Pharmacology, 2006